Evaluating a new device for managing take-home methadone for opioid use disorder patients.
COPA: A clinical program to evaluate benefits of a hand-held, automated, personalized oral liquid dispensing system for take-home methadone medication management for patients with opioid use disorder.
['FUNDING_SBIR_2'] · BERKSHIRE BIOMEDICAL CORPORATION · NIH-11168127
This study is testing a handy device that gives personalized doses of methadone to help people with opioid use disorder manage their medication at home, making it easier for them to stick to their treatment and improve their quality of life.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BERKSHIRE BIOMEDICAL CORPORATION (nih funded) |
| Locations | 1 site (DALLAS, UNITED STATES) |
| Trial ID | NIH-11168127 on ClinicalTrials.gov |
What this research studies
This research investigates a hand-held, automated system designed to dispense personalized doses of methadone for patients with opioid use disorder (OUD). The goal is to improve medication management by allowing patients to take their medication home, thereby reducing the need for daily clinic visits. The study will assess the acceptability and feasibility of this device, focusing on how it can enhance treatment adherence and overall patient quality of life. By using a mixed methods approach, the research will gather both quantitative and qualitative data from participants to understand their experiences and outcomes with the device.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who are currently receiving or are eligible for methadone treatment.
Not a fit: Patients who are not diagnosed with opioid use disorder or those who are not eligible for methadone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve medication adherence and quality of life for patients with opioid use disorder.
How similar studies have performed: Previous research has shown that flexible take-home dosing can improve treatment retention and patient outcomes, suggesting that this approach may be effective.
Where this research is happening
DALLAS, UNITED STATES
- BERKSHIRE BIOMEDICAL CORPORATION — DALLAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TIMBERLAKE, JOHN — BERKSHIRE BIOMEDICAL CORPORATION
- Study coordinator: TIMBERLAKE, JOHN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus